DWA
CUE icon

Dorsey Wright & Associates’s Cue Biopharma CUE Stock Holding History

Dorsey Wright & Associates’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21
Closed -$15K – 317
2020
Q2 		$15K Hold
21
– – ﹤0.01% 180
2020
Q1 		$9K Buy
+21
New +$10.2K ﹤0.01% 156

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Dorsey Wright & Associates's CUE Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Cue Biopharma (CUE) in Q3 2020, closing a stake of 21 shares — an estimated $15K sold.

Dorsey Wright & Associates first reported a position in CUE in Q1 2020 and held it in 2 quarters. The position peaked at $15K in Q2 2020. 92 funds tracked by Wall St. Rank hold CUE as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Cue Biopharma position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 21 Cue Biopharma shares in Q3 2020, an estimated $15K.
  • Dorsey Wright & Associates first reported a position in Cue Biopharma in Q1 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's Cue Biopharma position peaked at $15K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.